CompletedPHASE1, PHASE2NCT00895934

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Roland Walter, MD PhD
Fred Hutchinson Cancer Center
Intervention: vorinostat(drug)
Enrollment: 52 enrolled
Eligibility: 50 years · All sexes
Timeline: 2009 – 2013

Study locations (4)

Stanford University Hospitals and Clinics, Stanford, California, United States
Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
University of Washington Medical Center, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00895934 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials